We are fortunate to have partnered with some of the best entrepreneurs in the world and had the support of world class LPs who share our long term vision. Appreciate the opportunity to continue our mission.
CVS just put a number on the GLP-1 break-even question. Using Aetna claims, they estimate that at ~$350/month, medical savings roughly offset the drug cost over 3 years.
Compared with matched non-users, GLP-1 users had:
- 10-12% fewer ER visits in years 1 and 2
- 14% lower odds of a major cardiovascular event
- 34-42% fewer hospitalizations among those still on the drug at year 3
At today’s employer prices (~$617-766/mo), plans saved $9,400 per person on medical but spent $13,300 more on Rx. Net: +$3,900.
The interesting part: cash prices (~$299-349) and Medicare’s $245 pilot price are already below CVS’s break-even. The barrier isn’t what these drugs can be sold for. It’s what employers are paying.
Family coverage now costs $28,303 a year (KFF). That’s why employers are dropping GLP-1s, not because the drugs don’t work. At ~$350/mo, they wouldn’t have to choose.
A few call outs: it's a CVS white paper... (insert disclaimers). Observational. Diabetes and obesity pooled. The year-3 group (n≈4,000) is people who stayed on, who may differ from those who stopped. And CVS has a seat at this negotiating table.
Affordability drives access.
@ZReitano is a singular founder and this ep is MUST listen 👇
@ro has helped millions become healthier and happier, and the company journey is full of twists and turns that every builder can learn valuable lessons from.
Incredibly proud to have backed Z and the Ro team from day one!
My conversation with Zach Reitano (@ZReitano), co-founder and CEO of Ro
In four years he took Ro from a $250M run rate to over $3B, with about a third fewer people
Zach rarely does long conversations like this, so it was fun to talk about the details of what that took and everything happening in healthcare
Plus, his answer to the closing question is amazing
We discuss:
- the state of the US healthcare system
- refounding Ro
- strong attract, strong repel culture
- the notion of jobs over lives
- the power of celebrities in marketing
- the importance of tailwinds (AI, GLP-1s)
- trying to recreate his dad in software
Enjoy!
TIMESTAMPS
0:34 How Much Should We Spend on Health
4:59 The Patient Is Not the Customer
10:24 Inside Ro's Business
18:28 The Future of GLP-1s
25:46 Jobs Over Lives
30:02 The Turnaround
47:43 Where Healthcare Goes Next
1:00:27 Recreating His Dad in Software
1:06:33 Marketing Into Stigma
1:19:06 Zach's Hottest Take
1:20:58 The Kindest Thing
Tenacious, ambitious and incredibly principled… truly one of a kind founder. Proud of @ZReitano for telling the story that is really just beginning. Let’s go @ro!
My conversation with Zach Reitano (@ZReitano), co-founder and CEO of Ro
In four years he took Ro from a $250M run rate to over $3B, with about a third fewer people
Zach rarely does long conversations like this, so it was fun to talk about the details of what that took and everything happening in healthcare
Plus, his answer to the closing question is amazing
We discuss:
- the state of the US healthcare system
- refounding Ro
- strong attract, strong repel culture
- the notion of jobs over lives
- the power of celebrities in marketing
- the importance of tailwinds (AI, GLP-1s)
- trying to recreate his dad in software
Enjoy!
TIMESTAMPS
0:34 How Much Should We Spend on Health
4:59 The Patient Is Not the Customer
10:24 Inside Ro's Business
18:28 The Future of GLP-1s
25:46 Jobs Over Lives
30:02 The Turnaround
47:43 Where Healthcare Goes Next
1:00:27 Recreating His Dad in Software
1:06:33 Marketing Into Stigma
1:19:06 Zach's Hottest Take
1:20:58 The Kindest Thing
Z Reitano @ZReitano Nov 11 Article Refounding Ro to $3B+ Run Rate 30k feet in the air, I had a pit in my stomach. It’s December 2021 and I’m flying home to visit my parents. I’m looking at our 2021 results. It was ugly. Ro was growing at ~9% YoY. We were at a $270M
Z Reitano @ZReitano Nov 6 Article Introducing Ro Research Lab Two stories. Both start in 2005. In April 2005, the FDA approved the first GLP-1 for type 2 diabetes. Nine years later, one was approved for weight management. Since then, GLP-1-based medicines have
We just crossed $100M in run rate.
Four quarters ago, we were at $1M. Then this year alone, we grew 37.5x.
Not long before that, we did a hard pivot- handed our old customers to competitors, rebuilt from scratch, and relaunched with a few months of runway left.
The bet was: models think on GPUs but work happens on CPUs.
So every agent that writes code, opens a browser, or runs an RL job needs a composable computer that's isolated, stateful, and ready in milliseconds.
$1M to $100M in about a year puts us in the same cohort as the likes of Anthropic and Cursor. It’s humbling to share that lane with companies we’ve learned so much from.
Charles Barkley's transformation on Ro has been incredible. Read his story in People and check out our latest campaign with him.
people.com/charles-barkley-l…
Z Reitano @ZReitano Oct 29 Article Introducing Robin AI Of the ~1B using ChatGPT monthly, over 300M are using it for health and wellness related questions. It is the single most popular consumer AI use case. I love it. But, while it is immeasurably better
Some think of Yahoo! as an old business, decaying.
But somehow @jlanzone and team are doing the unexpected - and really turning it around into a relevant modern juggernaut.
Kudos to my friend Jim even if he sucks at fantasy football.
great ROI for its investors too.
Today, Baba raised a $40M Series A.
We give each Medicare member and their family a dedicated team of advocates and behavioral health experts to keep every part of their care moving forward. In a world obsessed with AI personal assistants, it’s never been more important to have expert humans in the loop to go the last mile, particularly in healthcare.
Our advocates have moved mountains for their patients - finding safe housing for the near-homeless, recertifying Medicaid for those about to lose their benefits, and getting financial assistance for people cutting their pills to afford groceries.
In the process, we’ve used AI to scale the impact this special team can have. And to truly teach AI to reason and execute like the best care coordinators, we’ve built the largest learning environment for the type of work that we do everyday.
There is still a lot to do: we’ve served fewer than 1% of the 70 million Americans on Medicare.
Baba does not lack capital or customer demand. Our ability to seize this opportunity is now limited by the capacity of our team. If you’re an exceptional engineer or operator in New York, come build with us: callbaba.com/join.
Our Series A was led by @FirstMarkCap , with @CVSHealth, @valtruis, @generalcatalyst, @geniusventures, and @GroundUpVC investing alongside them.